Current Reviews in Clinical and Experimental Pharmacology最新文献

{"title":"Fisetin, a Promising Anti-Cancer Flavonoid: A Brief Review of Its Biological Effects and Molecular Mechanisms in Lung Cancer Prevention and Therapy.","authors":"Ali Jahanban-Esfahlan, Parina Asgharian, Samin Mohammadi, Hadi Ghanbari, Solmaz Asnaashari","doi":"10.2174/0127724328344902250324062309","DOIUrl":"10.2174/0127724328344902250324062309","url":null,"abstract":"<p><strong>Introduction: </strong>Experimental evidence has demonstrated that compounds of natural origin possess adjuvant anti-cancer properties, and their combination with anti-cancer drugs has the potential to reduce drug resistance in cancer treatment exhibiting chemoprotective effects.</p><p><strong>Methods: </strong>Fisetin (FIS), a flavonoid-structured polyphenolic compound found in various vegetables and fruits, is used as a yellow/ochre coloring agent and shows diverse pharmacological and biological effects. FIS can modulate various signaling pathways in relation to oxidative stress, inflammation, cell proliferation, metastasis, and angiogenesis. Thus, FIS is proposed to be a beneficial agent for preventing and treating numerous human malignancies. Awareness of natural compound action mechanisms paves the way for scientific communities, healthcare organizations, and the pharmaceutical industry to develop and introduce new drugs to treat diseases. In this paper, the general properties of FIS were highlighted first, and later, using the Scopus database, all related scientific literature regarding the studies that investigated the effects of FIS on lung cancer was collected.</p><p><strong>Results: </strong>The critical points were extracted from the research works, and possible effects and molecular mechanisms of FIS on cancer cells were reviewed, and a comprehensive discussion about the roles of this phytochemical on different signaling pathways that were very crucial in lung cancer cells was provided.</p><p><strong>Conclusion: </strong>Finally, the current challenges and future perspectives of lung cancer prevention and therapy approaches using FIS were addressed.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":"52-74"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacogenetics of Statin-Induced Myopathy: Genetic Gatekeepers Shaping Precision Therapeutics.","authors":"Ali H Eid","doi":"10.2174/0127724328452142251110050640","DOIUrl":"10.2174/0127724328452142251110050640","url":null,"abstract":"","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":"92-95"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145557778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Gut Connection: A Narrative Review on the In-depth Analysis of Gut Microbiota and Metabolites in Depression.","authors":"Ayesha Sultana, Md Sadique Hussain, Mudasir Maqbool, Mohit Agrawal, Ajay Singh Bisht, Navneet Khurana, Gurvinder Singh, Rajesh Kumar","doi":"10.2174/0127724328332998250118182255","DOIUrl":"10.2174/0127724328332998250118182255","url":null,"abstract":"<p><p>Depression is a prevalent mood disorder with significant public health implications. Despite extensive research, its precise causes remain inadequately understood. Recently, interest has surged in the role of the gut microbiome and its metabolites in the pathophysiology of depression. This review aims to provide a comprehensive overview of the relationship between gut microbiota, its metabolites, and depression while exploring potential mechanisms influencing the efficacy of antidepressant medications. A narrative review methodology was employed, synthesizing recent studies utilizing a multi-omics approach. We examined alterations in gut microbiome composition and metabolite production in individuals diagnosed with depression, discussing the technical tools and methods commonly applied in this research area. The findings indicate that individuals with depression show significant alterations in gut microbiome composition, notably an imbalance in <i>Firmicutes, Bacteroidetes</i>, and <i>Actinobacteria</i>. Changes in metabolite production, including short-chain fatty acids, tryptophan, and bile acids, were also observed. Moreover, the review highlights that antidepressant medications may exert their therapeutic effects by modulating gut microbiota and its metabolites. This review emphasizes the intricate interplay between gut microbiota, its metabolites, and depression, revealing critical insights into the mechanisms underlying antidepressant efficacy. We recommend that future research focus on elucidating these interactions to develop innovative therapeutic strategies, potentially transforming the management of depression through microbiota-targeted approaches.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":"25-51"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breaking the Mold: Advances and Hurdles in Antifungal Resistance Management for Dermatophytes.","authors":"Zaid Ra'ed Alnsour, Mouiad Ra'ed Alnsour, Ayham Ra'ed Alnsour, Majd Majed Masadeh, Karem Hasan Alzoubi, Majed Mohammad Masadeh","doi":"10.2174/0127724328328331241217194034","DOIUrl":"10.2174/0127724328328331241217194034","url":null,"abstract":"<p><p>Examining antifungal resistance in dermatophytes is crucial in infectious diseases, dermatology, and clinical microbiology. The increasing occurrence of resistant infections and their influence on the effectiveness of therapy seem overwhelming. This study examines the present condition of antifungal resistance in dermatophytes, highlighting the need for ongoing and up-to-date research. Fungal diseases constantly change, and fungi have developed new resistance mechanisms. Here, we analyze the historical context of research on antifungal resistance, examining the variables that contribute to the development of resistance, such as the growing use of antifungals in clinical and agricultural contexts. We also explore the consequences of resistance to antifungal agents in clinical practice and public health. The review emphasizes the significance of new diagnostic technologies, like next-generation sequencing, in comprehending resistance mechanisms. It also underscores the crucial role of international collaboration in tackling this worldwide health concern. In conclusion, the paper emphasizes the need for continuous research to adjust to the evolving epidemiology of dermatophyte infections, create efficient treatment approaches, and guide public health interventions. This will ensure that the management of antifungal resistance is grounded in the most up-to-date scientific knowledge and optimal methods.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":"12-24"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurobiological Mechanisms of Ketamine Use, its Addiction, and Withdrawal: A Mini Review.","authors":"Sin Hui Ng, Yu Zhao Lee, Ming Ye Hong, Audrey Siew Foong Kow, Annette d'Arqom, Chau Ling Tham, Yu-Cheng Ho, MIng Tatt Lee","doi":"10.2174/0127724328362434250224105609","DOIUrl":"10.2174/0127724328362434250224105609","url":null,"abstract":"<p><p>Ketamine, a substance used for anesthesia and known for inducing dissociation, can lead to addiction and the development of severe withdrawal symptoms. Ketamine alters brain networks before affecting somesthetic sensation. Ketamine abuse was especially prevalent in East and Southeast Asia, and its popularity has continued to expand globally in recent decades. Ketamine is gaining popularity in the public and private sectors as a cheaper off-label depression treatment. Unfortunately, ketamine may cause side effects, such as heart and blood vessel instability, respiratory depression, liver injury, hallucinations, etc. The pain-relieving and mental effects of ketamine might induce reliance; thus, it should be used cautiously. This review highlights the neurobiological processes underpinnings of ketamine's addictive potential, withdrawal, and its effects on brain networks like the prefrontal cortex, hippocampus, and mesolimbic pathway, which play vital roles in decision-making, memory, and reward processing. In addition, the involvement of neurotransmitter systems, specifically glutamate and dopamine, in mediating the addictive properties of ketamine and the neuroadaptive changes that occurred during withdrawal are also discussed. It also explains that low-dose ketamine can alter the secretion of stress hormone cortisol and hypothalamic-pituitary-adrenal (HPA) axis dysregulation, possibly attributed to the current repurposing study of ketamine as a fast-acting antidepressant. Understanding these pathways is essential for developing effective ketamine addiction treatments, managing withdrawal symptoms, and possibly reversing brain changes for the betterment of human health and psychological well- being.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":"1-11"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143543861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Implications and Patient Outcomes Associated with otic Resistance in Saudi Arabian Intensive Care Unit Facilities: A Perspective.","authors":"Saad S Alqahtani, Muhammad H Sultan, Sivakumar S Moni, Renju Ravi, Ali Alshahrani, Santhosh Joseph Menachery","doi":"10.2174/0127724328391436250902082555","DOIUrl":"https://doi.org/10.2174/0127724328391436250902082555","url":null,"abstract":"<p><strong>Introduction: </strong>Antimicrobial Resistance (AMR) poses a significant global health threat, leading to increased morbidity, mortality, and healthcare costs. Intensive Care Units (ICUs) are particularly susceptible to AMR due to frequent invasive procedures, extended hospital stays, and the selective pressure exerted by broad-spectrum antibiotics. This review aims to shed light on the current landscape of antibiotic resistance within ICUs of Saudi hospitals. It also explores molecular patterns of bacterial resistance and identifies potential strategies to address this issue. Additionally, it discusses the challenges in implementing these strategies within the Saudi healthcare system.</p><p><strong>Methods: </strong>We conducted a literature search across electronic databases, including Web of Science, PubMed, EMBASE, Scopus, and Google Scholar, until September 30th, 2024, to identify relevant studies. Selected studies were analyzed to extract insights into prevailing bacterial resistance trends in Saudi ICUs and the molecular mechanisms responsible.</p><p><strong>Results: </strong>Our findings provide an overview of the current state of AMR in Saudi ICUs, including the emergence and prevalence of specific molecular patterns of bacterial resistance. Moreover, it presents potential strategies to combat antibiotic resistance, including antimicrobial stewardship programs, infection control measures, and the development of new antibiotics. It also highlights the inherent challenges in implementing these strategies within the unique healthcare landscape of Saudi Arabia.</p><p><strong>Discussion: </strong>The increasing emergence and spread of MDR bacteria in Saudi Arabia are attributed to the unoptimized antibiotic use, over-the-counter antibiotics without prescription, a high volume of international travellers, and challenges in adherence to infection control practices. Addressing the challenges and implementing effective prevention strategies are critical to maintaining antibiotic efficacy and combating AMR. Several strategies have been employed by the National AMR Committee, in partnership with WHO, to address antibiotic resistance in intensive care units.</p><p><strong>Conclusion: </strong>AMR in Saudi ICUs is a pressing concern requiring immediate attention. A multifaceted approach combining surveillance, education, and policy interventions is essential to overcome this issue. Addressing AMR is crucial for global efforts to preserve the efficacy of antibiotics and maintain the effectiveness of critical healthcare interventions.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145016312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MicroRNAs as Biomarkers and Therapeutic Targets in Treatment-Resistant Depression: Unveiling Diagnostic and Treatment Pathways.","authors":"Alaa A A Aljabali, Almuthanna Alkaraki, Omar Gammoh, Esam Qnais, Abdelrahim Alqudah, Walhan Alshaer, Vijay Mishra, Yachana Mishra, Mohamed El-Tanani","doi":"10.2174/0127724328381443250825092900","DOIUrl":"https://doi.org/10.2174/0127724328381443250825092900","url":null,"abstract":"<p><strong>Introduction: </strong>Treatment-Resistant Depression (TRD) is a complex clinical condition characterized by inadequate response to conventional antidepressant treatments. There is growing evidence that microRNAs (miRNAs) play a role in the underlying pathophysiology of TRD and may offer new avenues for diagnostics and therapy.</p><p><strong>Methods: </strong>A structured literature review of peer-reviewed publications indexed in PubMed, Scopus, and Web of Science was conducted. The search strategy included combinations of keywords such as \"treatment- resistant depression,\" \"microRNAs,\" \"biomarkers,\" and \"miRNA-based interventions.\" Articles were selected based on relevance to miRNA expression patterns in TRD, therapeutic modulation, and their clinical potential.</p><p><strong>Results: </strong>Dysregulation of several miRNAs-including miR-135a, miR-34a, and miR-155-was consistently observed in patients with TRD. These miRNAs were linked to impaired synaptic plasticity and persistent neuroinflammation. Therapeutic approaches using miRNA mimics or inhibitors showed potential in restoring neurobiological balance and enhancing response to traditional antidepressants. However, delivery system limitations and blood-brain barrier penetration remain significant challenges.</p><p><strong>Discussion: </strong>miRNAs appear to play a dual role in TRD, serving both as biomarkers for diagnosis and as targets for novel therapies. Integrating miRNA profiling into clinical workflows could enhance diagnostic precision and guide individualized treatment strategies. Translational barriers, such as delivery specificity and standardization of detection protocols, must be addressed before the widespread clinical application of this technology.</p><p><strong>Conclusion: </strong>This review highlights miRNAs as promising diagnostic and therapeutic tools in TRD. Continued advancements in delivery systems and validation of biomarker panels may pave the way for their clinical implementation in personalized psychiatry.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-obesity Treatments with Anti-inflammatory and Antioxidant Potential and their Effects on Obesity-related Metabolic and Cardiovascular Disorders: A Narrative Review.","authors":"Fani-Niki Varra, Michail Varras, Viktoria-Konstantina Varra, Panagiotis Theodosis-Nobelos","doi":"10.2174/0127724328392698250818071803","DOIUrl":"https://doi.org/10.2174/0127724328392698250818071803","url":null,"abstract":"<p><strong>Introduction: </strong>Obesity is a condition that affects a large part of the global population, and especially in the Western world, leading to a significant systemic inflammatory response in the body, characterized by modification of the secretory inflammatory cytokines and adipokines. The combination of fat accumulation and inflammation can lead to concomitant conditions, such as Insulin Resistance (IR) and increased production and release of fatty acids, ultimately enhancing the occurrence of conditions like metabolic and cardiovascular disorders, with inflammation and oxidative stress being implicated in these phenomena and appearing as important interconnecting factors. In this review, an attempt is made to analyze, in terms of their full scope of action, the pharmaceutical approaches against obesity, which affect fats, sugars, adipokines, and also the central nervous system.</p><p><strong>Methods: </strong>Using data from experimental animal procedures and clinical trials, the involvement of anti-obesity drugs against systemic chronic inflammation and oxidative stress, as well as in obesityrelated cardiometabolic disorders, is analyzed.</p><p><strong>Results: </strong>Anti-obesity treatments targeting more than one factor at the mechanistic level and limiting the body's inflammatory responses could contribute in multiple ways to improving metabolic and cardiovascular conditions and derangements. However, they carry a high risk of adverse effects, which may be reduced with the combination of such treatments, leading to a more favorable activity- to-hazard ratio and elucidation of the complete mechanistic properties of these treatments.</p><p><strong>Discussion: </strong>Until now, many gaps in the literature remain concerning one or more of these aspects for all these treatments. Through the prism of the multi-functional nature of these compounds, an attempt is made to clarify the multi-level nature of action of these substances against obesity, potentially allowing limiting the multi-drug treatment of these conditions, leading to the limitation of interactions, and the multiple side effects related to the drug combination.</p><p><strong>Conclusion: </strong>In order to achieve the above-mentioned objectives, in addition to investigating the full range of action of these anti-obesity drug treatments, the full history of their dose-dependent side effects and contraindications is required, through further clinical studies and analyses. These findings will shed light on the complete anti-inflammatory, antioxidant, and metabolic changes that anti-obesity treatments could offer, and the clinical manipulation of conditions associated with obesity, since the current misalignment and, in some cases, the mixed results between the already existing research groups lead to less definite conclusions.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144971978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunoglobulin Therapy in Patients with Painful Small Fiber Neuropathy: A Systematic Review.","authors":"Alaleh Alizadeh, Nafise Niknam, Soroush Morsali, Zeinab Ameri, Mohammad Rahmanian","doi":"10.2174/0127724328350286250727014322","DOIUrl":"https://doi.org/10.2174/0127724328350286250727014322","url":null,"abstract":"<p><strong>Introduction: </strong>Small fiber neuropathy (SFN) affects pain and autonomic function, and there is increasing evidence that immune pathways are linked to its pathology. Intravenous immunoglobulin (IVIG) has been proposed as a treatment option for patients with painful SFN but has yielded mixed results. This review evaluates the effectiveness of IVIGs in the treatment of painful SFN.</p><p><strong>Methods: </strong>According to PRISMA guidelines, a thorough literature search was conducted using five major electronic databases (PubMed, Google Scholar, Scopus, EMBASE, and Web of Science) up to August 17, 2023. Data extraction was performed independently by two reviewers, and quality assessments were performed using Joanna Briggs Institute tools. The PRISMA guidelines ensured the transparency of the review.</p><p><strong>Results: </strong>This systematic review included seven studies to evaluate the effectiveness of IVIG for the treatment of SFN. The review included 458 patients from various studies conducted between 2005 and 2023, covering various neuropathy subtypes such as idiopathic SFN, sarcoidosis-associated SFN, etc. Both double-blind RCTs reported no significant differences between IVIG and placebo in neuropathy severity or pain reduction. Retrospective cohort studies varied in quality and produced mixed results. Of note, some studies showed significant pain reduction with IVIG, while others did not. The effectiveness of IVIG on neuropathy severity and intraepidermal nerve fiber density was similarly variable, with some studies reporting efficacy and others indicate no significant changes. Overall, IVIG showed potential benefits, but the results were inconsistent across studies.</p><p><strong>Discussion: </strong>IVIG shows potential efficacy in select SFN subtypes, particularly autoimmuneassociated forms (e.g., TS-HDS/FGFR-3 positive), with some retrospective studies reporting pain and functional improvements. However, two high-quality RCTs found no significant benefit over placebo. Marked heterogeneity in study design, IVIG protocols, diagnostic criteria, and outcome measures limits comparability and generalizability. Adverse events, including infusion reactions were common. These findings highlight IVIG's possible role in immunologically mediated SFN but underscore the need for standardized protocols, biomarker-based patient selection, and large, wellcontrolled trials to establish definitive efficacy.</p><p><strong>Conclusion: </strong>Some evidence suggests the potential benefit of IVIG therapy for certain subgroups of patients with SFN. However, the overall effectiveness is still unclear, and further studies are needed.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanotechnology: A Potentially Powerful Tool for Attenuating Cisplatin-Induced Nephrotoxicity: A Narrative Review.","authors":"Hasan Ebrahimi Shahmabadi, Tahereh Zadeh Mehrizi, Mehdi Shafiee Ardestani","doi":"10.2174/0127724328374568250711183328","DOIUrl":"https://doi.org/10.2174/0127724328374568250711183328","url":null,"abstract":"<p><p>Cis-diamminedichloroplatinum (II) (cisplatin, CDDP) is one of the main anticancer drugs, used for the treatment of various malignancies. However, clinical application of this drug is associated with various side effects, prominently nephrotoxicity. One of the promising tools to decrease the side effects of the drug and simultaneously improve its therapeutic effects is the loading the drug into nanoparticles (NPs). This literature review focuses on the efficacy of various types of NPs, such as liposome, micelle, dendrimer, poly (lactic-co-glycolic acid), chitosan, alginate, curcumin (CUR), and metallic NPs to improve the therapeutic effects of CDDP and to decrease the nephrotoxicity. The results of these studies demonstrated that the reviewed NPs are able to decrease the nephrotoxic effects of CDDP in one of four different ways, including as a conjugating agent, encapsulating agent, antioxidant agent, or nanocarrier. Finally, among these reviewed NPs, liposomal NPs and the co-treatment with CUR as an antioxidant agent have more promising effects in reducing the toxicity of CDDP. Overall, the wide use of nanoliposomes in drug delivery systems due to their high stability, biocompatibility, drug loading capacity, and high bioavailability prompts the authors to propose liposomal CDDP delivery as a potent candidate for future studies. Moreover, because of the synergistic effects of CUR and CDDP on cancerous cells, the antioxidative properties of CUR in mitigating CDDP-induced nephrotoxicity, and the radiosensitizing influence of CUR, there is potential for the co-delivery of CDDP and CUR via liposomes to the tumor region.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144745276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}